Niu Gang, Chen Xiaoyuan
Molecular Imaging Program at Stanford, Department of Radiology, and Bio-X Program, Stanford University School of Medicine.
Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health (NIH).
Drug Deliv (Lond). 2009;3:109-113.
The parallel development of molecular imaging and drug delivery allows the combination of therapeutic agents with imaging moieties, which facilitates visualisation of the drug delivery process and provides a realtime readout on the efficacy of a therapeutic agent. Although challenging, it is feasible to construct a highly versatile, multifunctional single 'theranostic' probe for quantitative molecular imaging, targeted drug delivery and controlled drug release to obtain an effective therapeutic response. Compared with conventional methods for the evaluation of pharmacokinetics/pharmacodynamics, molecular imaging has advantages such as substantially decreasing the workload and increasing the volume of more precise data with statistical relevance. More importantly, molecular imaging techniques bridge the gap between pre-clinical and clinical research to develop candidate drugs that have the optimal target specificity, pharmacodynamics and efficacy. With the advancement and integration of technology in various fields, diverse types of targeted imaging probe coupled with drug delivery potential have been developed. Preliminary data have demonstrated that it is feasible and promising to use these targeted carriers for simultaneous target imaging and drug delivery.
分子成像与药物递送的同步发展使得治疗剂能够与成像部分相结合,这有助于可视化药物递送过程,并提供关于治疗剂疗效的实时读数。尽管具有挑战性,但构建一种高度通用的多功能单一“治疗诊断”探针用于定量分子成像、靶向药物递送和可控药物释放以获得有效的治疗反应是可行的。与评估药代动力学/药效学的传统方法相比,分子成像具有显著减少工作量以及增加具有统计学相关性的更精确数据量等优势。更重要的是,分子成像技术弥合了临床前研究与临床研究之间的差距,以开发具有最佳靶标特异性、药效学和疗效的候选药物。随着各领域技术的进步与整合,已开发出多种具有药物递送潜力的靶向成像探针。初步数据表明,使用这些靶向载体进行同步靶标成像和药物递送是可行且有前景的。